What is HC Wainwright's Estimate for CRSP FY2024 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - HC Wainwright issued their FY2024 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($4.83) per share for the year. HC Wainwright has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.08) per share. HC Wainwright also issued estimates for CRISPR Therapeutics' Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the prior year, the business posted ($1.41) EPS.

Several other equities analysts have also commented on the stock. Bank of America decreased their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Barclays cut their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $77.59.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded down $0.90 during trading hours on Wednesday, hitting $39.71. The company had a trading volume of 2,163,823 shares, compared to its average volume of 1,933,963. The company's fifty day moving average is $42.77 and its 200 day moving average is $46.66. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10. The stock has a market capitalization of $3.39 billion, a PE ratio of -14.03 and a beta of 1.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Capital Market Strategies LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at $461,000. KBC Group NV grew its position in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after buying an additional 57,696 shares in the last quarter. Capital Advisors Inc. OK grew its position in CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after buying an additional 22,583 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Finally, State Street Corp boosted its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.